Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a Healthcare company (Biotechnology) with a market capitalization of $858M. The Maz Rating grades it against the other companies in its sector.
Corvus Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.17, Corvus Pharmaceuticals, Inc. trades at 4.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -35.0%, return on invested capital of -32.4% and a free cash flow yield of -5.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 13.38. Over the past 52 weeks the share price ranged from $6.39 to $26.95, with a beta of 0.86.
Corvus Pharmaceuticals, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 12 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.